J84.841 Neuroendocrine cell hyperplasia of infancy

Name of the Condition

• Neuroendocrine cell hyperplasia of infancy

Summary

Neuroendocrine cell hyperplasia of infancy (NEHI) is a rare pediatric lung disorder characterized by an abnormal increase in neuroendocrine cells within the airways. These cells produce hormones that regulate airway function, and their overgrowth can disrupt normal breathing. NEHI primarily affects infants and young children, leading to symptoms like tachypnea, retractions, and hypoxemia, often mimicking other respiratory conditions such as asthma or infection. The condition is part of a broader group of childhood interstitial lung diseases.

Causes

The exact cause of NEHI remains unclear, but it is thought to involve a combination of genetic and developmental factors. Research suggests abnormalities in neuroendocrine cell regulation or signaling pathways may contribute to the hyperplasia. Environmental exposures or infections have not been definitively linked to NEHI, and most cases appear to occur sporadically without a clear trigger.

Risk Factors

• Age: Typically diagnosed in infants and young children, with symptoms appearing in the first few months of life.
• Gender: Slightly more common in males, though the reason is not well understood.
• Family history: No strong genetic predisposition has been identified, but rare familial cases have been reported.

Symptoms

• Persistent tachypnea (rapid breathing) without obvious cause.
• Intercostal or subcostal retractions during breathing.
• Hypoxemia (low blood oxygen levels) that may worsen with activity or feeding.
• Failure to thrive or poor weight gain due to increased respiratory effort.
• Cough, often dry and non-productive.

Diagnosis

Diagnosis requires a combination of clinical evaluation, imaging, and sometimes lung biopsy. High-resolution CT scans may show characteristic patterns like ground-glass opacities in specific lung regions. Bronchoscopy with biopsy can confirm the presence of increased neuroendocrine cells. Exclusion of other conditions, such as infection or congenital heart disease, is critical to avoid misdiagnosis.

Treatment Options

Treatment focuses on managing symptoms and supporting respiratory function. Supplemental oxygen is often used to maintain adequate oxygen levels. Nutritional support may be necessary to address failure to thrive. In severe cases, mechanical ventilation or other respiratory therapies might be required. No specific cure exists, and management is largely supportive.

Prognosis and Follow-Up

Most children with NEHI show gradual improvement over time, though symptoms may persist into early childhood. Long-term outcomes vary, with some experiencing residual respiratory issues. Regular follow-up with a pulmonologist is essential to monitor lung function and adjust treatment as needed. Many children outgrow the most severe symptoms by adolescence.

Complications

• Chronic respiratory insufficiency requiring ongoing oxygen therapy.
• Delayed growth or developmental issues due to persistent illness.
• Increased susceptibility to respiratory infections.
• Rarely, progression to more severe lung disease, though this is uncommon.

Lifestyle & Prevention

• Avoid exposure to secondhand smoke or environmental pollutants, which may exacerbate respiratory symptoms.
• Ensure timely vaccinations to reduce infection risk.
• Maintain a balanced diet to support growth and immune function.
• Follow medical advice for activity restrictions if oxygen levels are low.

When to Seek Professional Help

Seek immediate medical attention if your child experiences:

• Sudden worsening of breathing difficulty.
• Bluish skin or lips (cyanosis).
• Inability to feed or drink due to respiratory distress.
• High fever or signs of infection.

Tips for Medical Coders

When coding for neuroendocrine cell hyperplasia of infancy, use the ICD-10-CM code J84.841. Ensure documentation supports the diagnosis, including clinical findings, imaging results, and any biopsy or bronchoscopy reports. Note that this code is specific to infancy and should not be used for older patients. Verify that other potential causes of respiratory symptoms have been ruled out to justify the diagnosis.